Skip to content

Effect of Magnesium Sulphate Added to Mepivacaine Hydrochloride on Inferior Alveolar Nerve Block Success in Patients With Symptomatic Irreversible Pulpitis in Mandibular Molars: A Randomized Clinical Trial.

Effect of Magnesium Sulphate Added to Mepivacaine Hydrochloride on Inferior Alveolar Nerve Block Success in Patients With Symptomatic Irreversible Pulpitis in Mandibular Molars: A Randomized Clinical Trial.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04561921
Enrollment
56
Registered
2020-09-24
Start date
2020-10-22
Completion date
2021-11-01
Last updated
2020-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Success of Inferior Alveolar Nerve Block

Brief summary

the study is conducted to assess the effect of adding magnesium sulphate to mepivacaine HCl compared to mepivacaine HCl alone on the success of inferior alveolar nerve block in patients with symptomatic irreversible pulpitis in mandibular molars

Interventions

DRUGMagnesium sulfate

patients will be given an IANB injection by adding 0.18 mL of 10% magnesium sulphate to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe

DRUGMepivacaine-Levonordefrin Hydrochloride

patients will be given an IANB injection by adding 0.18 mL of sterile distilled water to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age between 18-55 years old. 2. Systemically healthy patient (ASA I or II). 3. Mandibular molar teeth with: * Preoperative sharp pain. * No widening in the periodontal ligament (PDL). * Vital response of pulp tissue to cold pulp tester (ethyl chloride spray)1. * Fully formed roots. 4. Positive patient's acceptance for participation in the study.

Exclusion criteria

1. Patients who had used any type of analgesic medication during the preceding 12 hours before the treatment. 2. Pregnant or nursing females. 3. Patients having significant systemic disorder (ASA III or IV). 4. Drug abusers and subjects who were on antidepressant medication. 5. Re-treatment cases. 6. Patients with a contraindication for the use of magnesium sulphate or those known to be allergic to any of the study medications.

Design outcomes

Primary

MeasureTime frameDescription
success of inferior alveolar nerve block measured using a numerical rating scale (NRS)15 minutes after injectionIntensity of pain 15 minutes after injection during access cavity and initial file placement is recorded by the patient using a numerical rating scale(where 0= no pain ,1-3 =mild pain ,4-6= moderate pain and 7-9= severe pain )

Contacts

Primary Contactalaa Ib mekhimar, B.D.S
alaa.ibrahim.ghazy@gmail.com01096404006

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026